{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:40:08Z","timestamp":1791906008576,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.pcd.2024.03.005","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T06:25:54Z","timestamp":1711779954000},"page":"268-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"18","author":[{"given":"Lixuan","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jine","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2024.03.005_bib1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/hep.32228","article-title":"Global burden of NAFLD and chronic liver disease among adolescents and young adults","volume":"75","author":"Paik","year":"2022","journal-title":"Hepatology"},{"issue":"10290","key":"10.1016\/j.pcd.2024.03.005_bib2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pcd.2024.03.005_bib3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.pcd.2024.03.005_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nature reviews. Gastroenterology & hepatology"},{"key":"10.1016\/j.pcd.2024.03.005_bib5","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.pcd.2024.03.005_bib6","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.pcd.2024.03.005_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.pcd.2024.03.005_bib8","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.pcd.2024.03.005_bib9","doi-asserted-by":"crossref","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","article-title":"Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice","volume":"302","author":"Trevaskis","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.pcd.2024.03.005_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","article-title":"EASL International Liver Foundation NAFLD Policy Review Collaborators. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe","volume":"72","author":"Lazarus","year":"2020","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.pcd.2024.03.005_bib11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"59","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.pcd.2024.03.005_bib12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.pcd.2024.03.005_bib13","article-title":"GLP-1 and underlying beneficial actions in Alzheimer's disease, hypertension, and NASH","volume":"12","author":"Li","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"10","key":"10.1016\/j.pcd.2024.03.005_bib14","first-page":"653","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. The lancet","volume":"9","author":"Sattar","year":"2021","journal-title":"Diabetes & endocrinology"},{"key":"10.1016\/j.pcd.2024.03.005_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.pcd.2024.03.005_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.pcd.2024.03.005_bib17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7584","key":"10.1016\/j.pcd.2024.03.005_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/bmj.39057.406644.68","article-title":"What is heterogeneity and is it important?","volume":"334","author":"Fletcher","year":"2007","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.pcd.2024.03.005_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"issue":"5","key":"10.1016\/j.pcd.2024.03.005_bib20","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pcd.2024.03.005_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cld.2017.08.007","article-title":"Pathophysiology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"22","author":"Manne","year":"2018","journal-title":"Clin. Liver Dis."},{"issue":"9","key":"10.1016\/j.pcd.2024.03.005_bib22","doi-asserted-by":"crossref","first-page":"ITC65","DOI":"10.7326\/AITC201811060","article-title":"Nonalcoholic fatty liver disease","volume":"169","author":"Wang","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.pcd.2024.03.005_bib23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: pathophysiology and management","volume":"45","author":"Carr","year":"2016","journal-title":"Gastroenterol. Clin. North Am."},{"key":"10.1016\/j.pcd.2024.03.005_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00431-013-2157-6","article-title":"Pediatric non-alcoholic fatty liver disease: an increasing public health issue","volume":"173","author":"Berardis","year":"2014","journal-title":"Eur. J. Pedia"},{"key":"10.1016\/j.pcd.2024.03.005_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/jgh.12666","article-title":"Childhood adiposity trajectories and risk of nonalcoholic fatty liver disease in adolescents","volume":"30","author":"Ayonrinde","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"22","key":"10.1016\/j.pcd.2024.03.005_bib26","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pcd.2024.03.005_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease","volume":"95","author":"Sandoval","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.pcd.2024.03.005_bib28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.pcd.2024.03.005_bib29","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1007\/s11695-018-3451-1","article-title":"The efficacy of energy-restricted diets in achieving preoperative eeight loss for bariatric patients: a systematic review","volume":"28","author":"Naseer","year":"2018","journal-title":"Obes. Surg."},{"issue":"4","key":"10.1016\/j.pcd.2024.03.005_bib30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cmet.2016.02.005","article-title":"Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity","volume":"23","author":"Magkos","year":"2016","journal-title":"Cell metabolism"},{"issue":"6","key":"10.1016\/j.pcd.2024.03.005_bib31","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pcd.2024.03.005_bib32","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1161\/ATVBAHA.114.303034","article-title":"Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease","volume":"34","author":"Byrne","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.pcd.2024.03.005_bib33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1017\/S0029665113001249","article-title":"Ectopic fat, insulin resistance and non-alcoholic fatty liver disease","volume":"72","author":"Byrne","year":"2013","journal-title":"Proc. Nutr. Soc."},{"issue":"9","key":"10.1016\/j.pcd.2024.03.005_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025269","article-title":"GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy","volume":"6","author":"Sharma","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pcd.2024.03.005_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pcd.2024.03.005_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031394","article-title":"Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL\/6 J mice","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pcd.2024.03.005_bib37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1037\/0003-066X.62.3.220","article-title":"Medicare\u2019s search for effective obesity treatments: diets are not the answer","volume":"62","author":"Mann","year":"2007","journal-title":"Am. Psychol."},{"issue":"6","key":"10.1016\/j.pcd.2024.03.005_bib38","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s11095-022-03302-1","article-title":"Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review","volume":"39","author":"Mahapatra","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.pcd.2024.03.005_bib39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0026-0495(94)90164-3","article-title":"Effect of glucagon-like peptide-1 (proglucagon 78\u2013107amide) on hepatic glucose production in healthy man","volume":"43","author":"Hvidberg","year":"1994","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.pcd.2024.03.005_bib40","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","article-title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","volume":"53","author":"Hsieh","year":"2010","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.pcd.2024.03.005_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","article-title":"Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease","volume":"8","author":"Targher","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.pcd.2024.03.005_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pcd.2024.03.005_bib43","doi-asserted-by":"crossref","first-page":"F231","DOI":"10.1152\/ajprenal.00432.2018","article-title":"Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus","volume":"316","author":"Tonneijck","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.pcd.2024.03.005_bib44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","article-title":"Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial","volume":"28","author":"Ruff","year":"2022","journal-title":"Nat Med"}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S175199182400069X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S175199182400069X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T04:08:43Z","timestamp":1716437323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S175199182400069X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S175199182400069X"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2024.03.005","relation":{},"ISSN":["1751-9918"],"issn-type":[{"value":"1751-9918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2024.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}